Loading...
 
Toggle Health Problems and D

Vitamin D reduced risk of death of Chronic Kidney Disease by 30 percent: Meta-analysis March 2013

Vitamin D Treatment and Mortality in Chronic Kidney Disease:

A Systematic Review and Meta-Analysis.

Am J Nephrol. 2013 Mar 5;37(3):239-248.
Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daurès JP, Argilés A.
RD-Néphrologie, Institut Universitaire de Recherche Clinique, Montpellier, France.

Background/Aims: Hypovitaminosis D has been associated with an increased cardiovascular mortality in the general population and in patients with chronic kidney disease (CKD). Still, whether prescribing vitamin D reduces the risk of mortality in renal patients remains controversial.

Methods: We searched PubMed, ClinicalTrials.gov and the Cochrane Library for long-term longitudinal studies comparing vitamin D compounds (25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and synthetic derivatives) to placebo or no treatment in renal patients, and which evaluated mortality, to perform a meta-analysis. Data concerning study quality, population and effect size were extracted independently by two investigators using predefined forms.

Results: Fourteen observational studies (194,932 patients) met all eligibility criteria. Most studies were performed in hemodialysis patients and all used calcitriol or synthetic analogues. In a random effects meta-analysis, receiving any vitamin D therapy significantly reduced the risk of all-cause mortality (relative risk 0.73, 95% CI 0.65-0.82). The relative risk of death was 0.72 (95% CI 0.65-0.80) after 3 years of therapy and 0.67 (95% CI 0.45-0.98) after 5 years. In meta-regression, the risk reduction was shown to be greater in patients with higher parathyroid hormone serum levels (p = 0.01). The risk of cardiovascular mortality was also significantly reduced in patients receiving any vitamin D derivative (relative risk 0.63, 95% CI 0.44-0.92).

Conclusion: Therapies with 1,25-dihydroxyvitamin D and analogues are associated with reduced mortality in CKD patients, and particularly in those suffering from secondary hyperparathyroidism. These results, based on observational evidence, are supportive of prescribing vitamin D therapies to CKD patients, while respecting good practice guidelines.

Copyright © 2013 S. Karger AG, Basel.

PMID: 23467111

Figure 3

Image


PDF is attached at the bottom of this page

Strange that they looked at vitamin D, rather than the active form of vitamin D which is typically used for Chronic Kidney Disease

Yet another meta-analysis which appears to ignore how much vitamin D was used by each of the trials.

See also VitaminDWiki

Image

Attached files

ID Name Comment Uploaded Size Downloads
2187 CKD Feb 3.jpg admin 11 Mar, 2013 54.78 Kb 1415
2186 CKD meta-analysis Feb 2013.pdf admin 11 Mar, 2013 147.85 Kb 885